Active, not recruiting
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
NCT04994132· Phase 3· Children's Oncology Group· Source
Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
NCT04546399· Phase 2· National Cancer Institute (NCI)· Source
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
NCT04322318· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
NCT03817398· Phase 2· Children's Oncology Group· Source
Recruiting
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
NCT03959085· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
NCT03907488· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
NCT03533582· Phase 3· Children's Oncology Group· Source
Recruiting
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
NCT03126916· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
NCT02724579· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
NCT03007147· Phase 3· Children's Oncology Group· Source
Active, not recruiting
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
NCT02981628· Phase 2· Children's Oncology Group· Source
Active, not recruiting
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
NCT02567435· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
NCT02521493· Phase 3· Children's Oncology Group· Source
Recruiting
Project: Every Child for Younger Patients With Cancer
NCT02402244· Children's Oncology Group· Source
Active, not recruiting
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
NCT02166463· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
NCT02112916· Phase 3· National Cancer Institute (NCI)· Source
Active, not recruiting
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02176967· Phase 3· Children's Oncology Group· Source